Amplifications of MDM2 or MDMX are frequently found in sarcoma, glioblastoma, retinoblastoma and breast cancer, providing an interesting therapeutic target, i.e., re-activation of wild-type p53 by inhibition of MDM2/MDMX-p53 interaction [36]. This evidence concerns the gene MDM4 and glioblastoma.